CAS: 2290608-13-6
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide REF: 3D-QRD60813CAS: 2290608-13-6 | Min. 95% | A consultar | Mar 15 Abr 25 |
 | VT103 REF: TM-T62077CAS: 2290608-13-6 | 98.73% | 124,00 €~3.690,00 € | Mar 22 Abr 25 |
N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide
CAS:2290608-13-6
Please enquire for more information about N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide including the price, delivery time and more detailed …
Fórmula:
C18H17F3N4O2S
Pureza:
Min. 95%
Peso molecular:
410.4 g/mol
Ref: 3D-QRD60813
| 10mg | 1.011,00 € | ||
| 25mg | 1.648,00 € | ||
| 50mg | 2.637,00 € |
Entrega estimada en Estados Unidos, el Martes 15 de Abril de 2025
VT103
CAS:2290608-13-6
VT103, an oral TEAD1 palmitoylation inhibitor, shows promise against various cancers by disrupting YAP/TAZ-TEAD interactions.
Fórmula:
C18H17F3N4O2S
Pureza:
98.73%
Forma y color:
Liquid
Peso molecular:
410.41
Ref: TM-T62077
| 1mg | 124,00 € | ||
| 5mg | 298,00 € | ||
| 10mg | 472,00 € | ||
| 25mg | 847,00 € | ||
| 50mg | 1.378,00 € | ||
| 100mg | 1.872,00 € | ||
| 1mL*10mM (DMSO) | 328,00 € |
Entrega estimada en Estados Unidos, el Martes 22 de Abril de 2025
